Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases

Jing,Feifeng; Kim,Hun Jin; Kim,Chang Hyun; Kim,Young Jin; Lee,Jae Hyuk; Kim,Hyeong Rok

doi:10.3892/ijo.2015.2844

Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases

Authors:
- Feifeng Jing
- Hun Jin Kim
- Chang Hyun Kim
- Young Jin Kim
- Jae Hyuk Lee
- Hyeong Rok Kim
View Affiliations

Affiliations: Department of Surgery, Chonnam National University Medical School and Hwasun Hospital, Gwangju, Republic of Korea, Department of Pathology, Chonnam National University Medical School and Hwasun Hospital, Gwangju, Republic of Korea
Published online on: January 23, 2015 https://doi.org/10.3892/ijo.2015.2844
Pages: 1582-1588

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CD44 and CD133 mRNA expression as cancer stem cell markers in colorectal cancer were correlated with synchronous hepatic metastases and the clinicopathological factors, including patient survival. The CD44 and CD133 mRNA levels in 36 primary colorectal adenocarcinomas with synchronous hepatic metastasis were analyzed by reverse transcriptase polymerase chain reaction, with normalization relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Immunohistochemical analysis was performed on samples with typical mRNA expression patterns to investigate protein expression. Both CD44 and CD133 gene expressions were highest in hepatic metastasis tissue, followed by colorectal cancer and normal mucosa. The differences were statistically significant among groups of normal mucosa, colorectal cancer and hepatic metastasis tissue. CD44 mRNA expression was significantly associated with the tumor location (P=0.019) and histology (P=0.026). With a median follow-up period of 38 months, the 5-year disease-free survival rate of the patients with high CD44 mRNA expression in the CD44 hepatic metastasis tissue group was significantly lower than that of the patients with low expression (P=0.002). While the mRNA expressions in groups of CD44 colorectal tumor, CD133 colorectal tumor, and CD133 hepatic metastasis tissue were not significant. CD44 and CD133 mRNA were highly correlatively co-expressed in colorectal cancer with hepatic metastases. CD44 expression was an independent factor associated with patient survival, while CD133 did not show this pattern. Thus, CD44 is a more reliable marker for predicting hepatic metastases and survival. Larger prospective studies are required to confirm these findings.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2	Sakai Y: Current topics in colorectal liver metastasis. Int J Clin Oncol. 16:451. 2011. View Article : Google Scholar : PubMed/NCBI
3	Van Cutsem E, Lambrechts D, Prenen H, Jain RK and Carmeliet P: Lessons from the adjuvant bevacizumab trial on colon cancer: what next? J Clin Oncol. 29:1–4. 2011. View Article : Google Scholar
4	Huang X, Sheng Y and Guan M: Co-expression of stem cell genes CD133 and CD44 in colorectal cancers with early liver metastasis. Surg Oncol. 21:103–107. 2012. View Article : Google Scholar
5	Galizia G, Gemei M, Del Vecchio L, et al: Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer. Arch Surg. 147:18–24. 2012. View Article : Google Scholar : PubMed/NCBI
6	Anderson EC, Hessman C, Levin TG, Monroe MM and Wong MH: The role of colorectal cancer stem cells in metastatic disease and therapeutic response. Cancers (Basel). 3:319–339. 2011. View Article : Google Scholar :
7	Hu Y and Fu L: Targeting cancer stem cells: a new therapy to cure cancer patients. Am J Cancer Res. 2:340–356. 2012.PubMed/NCBI
8	Yu ZR, Pestell TG, Lisanti MP and Pestell RG: Cancer stem cells. Int J Biochem Cell Biol. 44:2144–2151. 2012. View Article : Google Scholar : PubMed/NCBI
9	Soltanian S and Matin MM: Cancer stem cells and cancer therapy. Tumour Biol. 32:425–440. 2011. View Article : Google Scholar : PubMed/NCBI
10	Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y, Uraoka N, Anami K, Sentani K, Oue N and Yasui W: Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int. 62:112–119. 2012. View Article : Google Scholar : PubMed/NCBI
11	Bendardaf R, Algars A, Elzagheid A, Korkeila E, Ristamaki R, Lamlum H, Collan Y, Syrjanen K and Pyrhonen S: Comparison of CD44 expression in primary tumours and metastases of colorectal cancer. Oncol Rep. 16:741–746. 2006.PubMed/NCBI
12	Bird NC, Mangnall D and Majeed AW: Biology of colorectal liver metastases: a review. J Surg Oncol. 94:68–80. 2006. View Article : Google Scholar : PubMed/NCBI
13	Jaggupilli A and Elkord E: Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol. May 30–2012. View Article : Google Scholar : PubMed/NCBI
14	Dalerba P, Dylla SJ, Park IK, et al: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 104:10158–10163. 2012. View Article : Google Scholar
15	Su YJ, Lai HM, Chang YW, Chen GY and Lee JL: Direct reprogramming of stem cell properties in colon cancer cells by CD44. EMBO J. 30:3186–3199. 2011. View Article : Google Scholar : PubMed/NCBI
16	Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and De Maria R: Identification and expansion of human colon cancer-initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar
17	Haraguchi N, Ohkuma M, Sakashita H, Matsuzaki S, Tanaka F, Mimori K, Kamohara Y, Inoue H and Mori M: CD133⁺CD44⁺ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol. 15:2927–2933. 2008. View Article : Google Scholar : PubMed/NCBI
18	O’Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 445:106–110. 2007. View Article : Google Scholar
19	Bao SD, Wu QL, McLendon RE, Hao YL, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
20	Frank NY, Pendse SS, Lapchak PH, Margaryan A, Shlain D, Doeing C, Sayegh MH and Frank MH: Regulation of progenitor cellfusionbyABCB5P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem. 278:47156–47165. 2003. View Article : Google Scholar : PubMed/NCBI
21	Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W and Frank MH: ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 65:4320–4333. 2005. View Article : Google Scholar : PubMed/NCBI
22	Horst D, Kriegl L, Engel J, Kirchner T and Jung A: Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 27:844–850. 2009. View Article : Google Scholar : PubMed/NCBI
23	Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, Miki C and Kusunoki M: Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 16:3488–3498. 2009. View Article : Google Scholar : PubMed/NCBI
24	Botchkina IL, Rowehl RA, Rivadeneira DE, Karpeh MS Jr, Crawford H, Dufour A, Ju J, Wang Y, Leyfman Y and Botchkina GI: Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. Cancer Genomics Proteomics. 6:19–29. 2009.PubMed/NCBI
25	Botchkina GI, Zuniga ES, Das M, et al: New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells. Mol Cancer. 9:1922010. View Article : Google Scholar : PubMed/NCBI
26	Chen KL, Pan F, Jiang H, Chen JF, Pei L, Xie FW and Liang HJ: Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+) CD44(high) metastatic subset in HCT116 colon cancer cells. Clin Exp Metastasis. 28:751–763. 2011. View Article : Google Scholar : PubMed/NCBI
27	Nagata T, Sakakura C, Komiyama S, et al: Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer. Anticancer Res. 31:495–500. 2011.PubMed/NCBI
28	Hou Y, Zou QF, Ge RL, Shen F and Wang YZ: The critical role of CD133⁺CD44^+/high tumor cells in hematogenous metastasis of liver cancers. Cell Res. 22:259–272. 2012. View Article : Google Scholar :
29	Bellizzi A, Sebastian S, Ceglia P, et al: Co-expression of CD133⁺/CD44⁺ in human colon cancer and liver metastasis. J Cell Physiol. 228:408–415. 2013. View Article : Google Scholar
30	Huh JW, Kim HR, Kim YJ, Lee JH, Park YS, Cho SH and Joo JK: Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int. 59:241–246. 2009. View Article : Google Scholar : PubMed/NCBI
31	Ohji Y, Yao T, Eguchi T, Yamada T, Hirahashi M, Iida M and Tsuneyoshi M: Evaluation of risk of liver metastasis in colorectal adenocarcinoma based on the combination of risk factors including CD10 expression: Multivariate analysis of clinicopathological and mmunohistochemical factors. Oncol Rep. 17:525–530. 2007.PubMed/NCBI
32	Park JJ, Kwon JH, Oh SH, et al: Differential expression of CD133 based on microsatellite instability status in human colorectal cancer. Mol Carcinog. 53:E1–E10. 2014. View Article : Google Scholar
33	Jones RJ: Cancer stem cells - clinical relevance. J Mol Med (Berl). 87:1105–1110. 2009. View Article : Google Scholar
34	Papailiou J, Bramis KJ, Gazouli M and Theodoropoulos G: Stem cells in colon cancer. A new era in cancer theory begins. Int J Colorectal Dis. 26:1–11. 2011. View Article : Google Scholar
35	Baumann M, Krause M and Hill R: Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer. 8:545–554. 2008. View Article : Google Scholar : PubMed/NCBI
36	Eyler CE and Rich JN: Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 26:2839–2845. 2008. View Article : Google Scholar : PubMed/NCBI
37	Frank NY, Schatton T and Frank MH: The therapeutic promise of the cancer stem cell concept. J Clin Invest. 120:41–50. 2010. View Article : Google Scholar : PubMed/NCBI
38	Li M, Li JY, Zhao AL and Gu J: Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas. Oncology. 73:52–57. 2007. View Article : Google Scholar
39	Chung CK, Zaino RJ and Stryker JA: Colorectal carcinoma: evaluation of histologic grade and factors influencing prognosis. J Surg Oncol. 21:143–148. 1982. View Article : Google Scholar : PubMed/NCBI
40	Umpleby HC, Bristol JB, Rainey JB and Williamson RC: Survival of 727 patients with single carcinomas of the large bowel. Dis Colon Rectum. 27:803–810. 1984. View Article : Google Scholar : PubMed/NCBI
41	Kazama Y, Watanabe T, Kanazawa T, Tanaka J, Tanaka T and Nagawa H: Poorly differentiated colorectal adenocarcinomas show higher rates of microsatellite instability and promoter methylation of p16 and hMLH1: a study matched for T classification and tumor location. J Surg Oncol. 97:278–283. 2008. View Article : Google Scholar
42	Mulder JW, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, Offerhaus GJ and Pals ST: Colorectal cancer prognosis and expression of exon-v6- containing CD44 proteins. Lancet. 344:1470–1472. 1994. View Article : Google Scholar : PubMed/NCBI
43	Weg-Remers S, Anders M, von Lampe B, Riecken EO, Schuder G, Feifel G, Zeitz M and Stallmach A: Decreased expression of CD44 splicing variants in advanced colorectal carcinomas. Eur J Cancer. 34:1607–1611. 1998. View Article : Google Scholar
44	Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L and Zlobec I: Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer. 103:382–390. 2010. View Article : Google Scholar : PubMed/NCBI
45	Horst D, Kriegl L, Engel J, Kirchner T and Jung A: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 99:1285–1289. 2008. View Article : Google Scholar : PubMed/NCBI
46	Kojima M, Ishii G, Atsumi N, Fujii S, Saito N and Ochiai A: Imunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci. 99:1578–1583. 2008. View Article : Google Scholar : PubMed/NCBI
47	Li CY, Li BX, Liang Y, et al: Higher percentage of CD133(+) cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med. 7:562009. View Article : Google Scholar
48	Choi D, Lee HW, Hur KY, Kim JL, Park GS, Jang SH, Song YS, Lang KS and Paik SS: Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol. 15:2258–2264. 2009. View Article : Google Scholar : PubMed/NCBI
49	Huh JW, Park YS, Lee JH, Kim HR, Shin MG and Kim YJ: CD133 mRNA expression and microsatellite instability in colorectal carcinoma. J Surg Oncol. 102:765–770. 2010. View Article : Google Scholar : PubMed/NCBI
50	Zlobec I, Terracciano L, Jass JR and Lugli A: Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch. 451:763–769. 2007. View Article : Google Scholar : PubMed/NCBI